Skip to main
LSTA

LSTA Stock Forecast & Price Target

LSTA Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lisata Therapeutics Inc. has demonstrated promising advancements in its investigational drug, certepetide, particularly highlighted by positive overall survival trends and four complete responses observed in a recent study cohort. The encouraging data from Cohort B indicate that a second dose of certepetide may enhance progression-free survival (PFS) and overall response rate (ORR) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). This clinical progress positions the company favorably within the pharmaceutical sector, underscoring its potential for significant contributions to cancer treatment solutions.

Bears say

Lisata Therapeutics Inc faces significant risks that could adversely impact its stock performance, primarily due to the uncertainty surrounding the success of its investigational product, certepetide, in clinical trials. The company could struggle to secure the necessary funding to continue developing its candidate therapies, which poses a threat to its operational capabilities. In addition, any failed or inconclusive clinical trials could further stagnate progress, limiting the potential for future commercialization and undermining confidence in the company's strategic outlook.

LSTA has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lisata Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lisata Therapeutics Inc (LSTA) Forecast

Analysts have given LSTA a Strong Buy based on their latest research and market trends.

According to 2 analysts, LSTA has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lisata Therapeutics Inc (LSTA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.